Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 359

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 359
---
 are able to confirm clinical diagnoses, forecast disease progression, guide early symptom detection, inform family planning, genetic counseling, and facilitate clinical trial enrollment. This test is intended for patients with personal or familial indications of hereditary cancer. However, it is not designed for somatic mutation detection in tumors. Oncology: Somatic Profiling (Mutation) Cancer Test The genetic test focuses on multi -biomarkergenes related to the homologous recombination repair pathway, aiding in the identification of prostate cancer patients who could benefit from targeted therapies. It analyzes tumor tissue and/or peripheral blood samples to detect germline mutations, assisting in risk assessment for patients and providing disease mechanism insights for optimal treatment decisions. This service is intended for cancer patients seeking accurate diagnoses to enable their physicians to choose the most effective treatments to improve recovery prospects. Oncology: Onco-hematology Panel This diagnostic test identifies pathogenic variants in 30 genes associated with myelodysplastic syndromes, myeloproliferative neoplasms, and leukemia. It also evaluates over 119 RNA fusions linked to leukemia development. The test simultaneously analyzes DNA for point mutations, small deletions, insertions, and copy number variants (such as SNVs, indels, CNVs), and RNA for chromosomal rearrangements, providing a comprehensive genetic profile in one single sample. The precise identification of genetic alterations enables informed diagnosis, patient stratification, and the selection of personalized treatments based on specific genomic events. Genetic and Rare Diseases: Chromosomal Microarray (“CMA”) CMA detects genetic anomalies and syndromes not identifiable through conventional karyotyping (chromosome imaging). This diagnostics service is especially adept at analyzing chromosome structure, copy number, and segregation, thus offering critical insights into a wide range of disorders, including cancers, developmental conditions, and fetal anomalies. The test requires a blood sample and is geared towards pediatric patients with complex diagnoses, individuals with developmental delays, intellectual disabilities, autism spectrum disorder, congenital anomalies, and those with a history of multiple pregnancy losses. Genetic and Rare Diseases: Clinical Exome This genetic test is designed to diagnose rare genetic disorders by evaluating the exons of up to 6,704 genes, which may explain symptoms associated with undiagnosed diseases. It utilizes blood samples and is available for individual patients or in a trio format that includes samples of the patient’s biological parents. This test is appropriate for preconception, neonatal, childhood, and adult patients, particularly those with rare Mendelian diseases or